Chimerix’s (CMRX) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Chimerix (NASDAQ:CMRX) in a research report report published on Wednesday, Marketbeat.com reports. They currently have a $8.55 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $11.00.

Separately, Wedbush reaffirmed an “outperform” rating and issued a $7.00 target price (up previously from $6.00) on shares of Chimerix in a research report on Tuesday, February 18th.

Chimerix Stock Performance

NASDAQ:CMRX opened at $8.43 on Wednesday. Chimerix has a 12 month low of $0.75 and a 12 month high of $8.47. The company has a market cap of $758.16 million, a PE ratio of -8.97 and a beta of 0.32. The company has a 50 day simple moving average of $4.24 and a two-hundred day simple moving average of $2.26.

Insider Activity

In other news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares of the company’s stock, valued at $2,755,405.56. The trade was a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 20,760 shares of company stock valued at $91,175 in the last 90 days. Company insiders own 13.10% of the company’s stock.

Institutional Investors Weigh In On Chimerix

A number of hedge funds have recently modified their holdings of CMRX. Bender Robert & Associates bought a new stake in shares of Chimerix during the 4th quarter valued at $37,000. Susquehanna Fundamental Investments LLC bought a new position in Chimerix in the 4th quarter worth $59,000. Jane Street Group LLC bought a new position in Chimerix in the 4th quarter worth $62,000. Diadema Partners LP bought a new position in Chimerix in the 4th quarter worth $101,000. Finally, Squarepoint Ops LLC bought a new position in Chimerix in the 4th quarter worth $130,000. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.